Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies

<!DOCTYPE html> <html lang="en"> <head> <meta charset="UTF-8"> <title> Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies </title> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <link rel="canonical" href="https://www.biopharmatrend.com/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/" />  <script async src="https://www.googletagmanager.com/gtag/js?id=G-YK7FCK71TD"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-YK7FCK71TD'); </script> <meta name="description" content="" /> <meta name="keywords" content="" />  <meta name="twitter:card" content="summary_large_image"> <meta name="twitter:title" content="Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies"> <meta name="twitter:description" content=""> <meta name="twitter:image" content="https://www.biopharmatrend.com/files/blog/social/Updated_Graph2_and_Table2a_and_Chart_Combo.png">  <meta property="og:type" content="article" /> <meta property="og:url" content="https://www.biopharmatrend.com/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/" /> <meta property="og:title" content="Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies" /> <meta property="og:description" content="" /> <meta property="article:published_time" content="2024-04-08T16:16:21+00:00"> <meta property="article:modified_time" content="2024-04-08T16:16:21+00:00"> <meta name="author" content="Dimitrios Skaltsas, Bara Badwan, Panos Karelis"> <meta property="og:image" content="https://www.biopharmatrend.com/files/blog/social/Updated_Graph2_and_Table2a_and_Chart_Combo.png"> <script type="application/ld+json">{ "@context": "https://schema.org", "@type": "Article", "headline": "Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies", "datePublished": "2024-04-08T16:16:21+00:00", "dateModified": "2024-04-08T16:16:21+00:00", "description": "Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike. With biotech firms often going public before generating revenue, valuations hinge on the potential for FDA approval of their assets. Herein lies the power of artificial intelligence (AI): by predicting the likelihood of success for these assets, we can uncover undervalued companies, offering a strategic edge not only to hedge funds and VCs but also to big pharma companies considering acquisitions. In this dynamic landscape, projected to see M&A activities reaching as high as $275B in 2024, the ability to discern and invest in promising biotech assets early is crucial.", "image": "https://www.biopharmatrend.com/files/blog/social/Updated_Graph2_and_Table2a_and_Chart_Combo.png", "url": "https://www.biopharmatrend.com/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://www.biopharmatrend.com/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/" }, "publisher": { "@type": "Organization", "name": "BiopharmaTrend", "url": "https://www.biopharmatrend.com", "logo": { "@type": "ImageObject", "url": "https://www.biopharmatrend.com/static/img/bpt_logo.png" } }, "author": [ { "@type": "Person", "name": "Dimitrios Skaltsas", "url": "https://www.biopharmatrend.com/contributor/2403/" }, { "@type": "Person", "name": "Bara Badwan", "url": "https://www.biopharmatrend.com/contributor/2404/" }, { "@type": "Person", "name": "Panos Karelis", "url": "https://www.biopharmatrend.com/contributor/2405/" } ] }</script> <style type="text/css"> .ap-chart-load svg { width: 100%; } .post-meta .author-linkein-icon { width: 1em; vertical-align: baseline; } .text-miniblock { display: inline-block; box-shadow: 0 0 6px -1px forestgreen; background: white; padding: 0.5rem; } .post .text-miniblock a { color: black; } .post .text-miniblock a:hover, .post .text-miniblock a:active { color: #333; text-decoration: underline; } .text-miniblock-right { float: right; margin: 0 0 1rem 1rem; max-width: 14rem; } .subscribe-block { background-color: deepskyblue; color: white; margin-top: 1.5rem; margin-bottom: 2rem; padding-top: 1.5rem; padding-bottom: 1.5rem; width: calc(50% + 100vw); padding-left: calc(50vw - 50%); padding-right: 50vw; margin-left: calc(50% - 50vw); position: relative; } .subscribe-block > .subscribe-inner { background-image: url('/files/subscription-bg.png'); background-position: right bottom; background-size: auto 120%; background-repeat: no-repeat; } .mobile-only { display: none; } @media screen and (max-width: 34em) { .text-miniblock-right { float: none; margin: 1rem 0; max-width: 100%; } .subscribe-block > .subscribe-inner { background-image: unset; } .mobile-only { display: block; } } </style> <link rel="shortcut icon" href="/static/favicon.ab1145f4d518.ico" /> <link rel="stylesheet" type="text/css" href="/static/css/main.6dead4e2266d.css" /> </head> <body> <div id="main-preheader"> <div class="container block-preheader"> <div id="logo-top"> <a href="/"><b>BioPharmaTrend</b></a>  </div> <div class="burger-container"> <div class="burger-button-container"> <button type="button" class="burger-button" onclick="document.documentElement.classList.toggle('blockfix');this.parentElement.parentElement.classList.toggle('active');"> <div class="burger-line burger-line-1"></div> <div class="burger-line burger-line-2"></div> <div class="burger-line burger-line-3"></div> </button> </div>  <div id="main-search-menu"> <div class="top-search"> <form action="/search/" class="top-search-form"> <button type="submit" class="btn btn-default"><i class="glyphicon glyphicon-search"></i></button> <input type="text" name="q" value="" size="10" class="form-control form-control-inline" required="" placeholder="e.g. 'quantum tech' or 'stem cell'"> <input type="hidden" name="section" value="insights"> </form> <span class="top-search-switcher button" onclick="this.parentElement.classList.toggle('active')"> <span class="glyphicon glyphicon-search"></span> <span class="glyphicon glyphicon-remove"></span> </span> </div> <span class="top-search-switcher button"> <span class="glyphicon glyphicon-search"></span> </span> </div>  <nav id="main-menu"> <div class="mobile-menu-item"> <a class="top-menu-link mobile-menu-item-title" href="/section/news/"><b>Latest News</b></a> </div> <div class="mobile-menu-item"> <b class="mobile-menu-item-title" onclick="this.parentElement.classList.toggle('active')">All Topics <span class="caret"></span></b> <div class="sub-menu-container"> <ul class="sub-menu"> <li><a class="top-menu-link" href="/topic/bioeconomy-society/">Bioeconomy & Society</a></li> <li><a class="top-menu-link" href="/topic/ai-digital/">AI & Digital</a></li> <li><a class="top-menu-link" href="/topic/startups/">Startups & Deals</a></li> <li><a class="top-menu-link" href="/topic/neurotech/">NeuroTech</a></li> <li><a class="top-menu-link" href="/topic/clinical-trials/">Clinical Trials</a></li> <li><a class="top-menu-link" href="/topic/synbio/">Biotech</a></li> <li><a class="top-menu-link" href="/topic/tools-methods/">Tools & Methods</a></li> <li><a class="top-menu-link" href="/topic/healthtech/">HealthTech</a></li> <li><a class="top-menu-link" href="/topic/aging-research/">Aging & Longevity</a></li> <li><a class="top-menu-link" href="/topic/contract-research/">Contract Research</a></li> <div class="sub-menu-margin"></div>  <li><a class="top-menu-link" href="/section/latest/">Latest insights</a></li> <li><a class="top-menu-link" href="/premium-content/">Premium Content</a></li> <div class="sub-menu-margin" style="border-bottom: 1px solid limegreen;"></div> <li><a class="top-menu-link" href="/knowledge-center/">Knowledge Center</a></li> </ul> </div> </div> <div class="mobile-menu-item"> <a class="top-menu-link mobile-menu-item-title" href="/section/interviews/"><b>Interviews</b></a> </div>  <div class="mobile-menu-item"> <b class="mobile-menu-item-title" onclick="this.parentElement.classList.toggle('active')">Companies <span class="caret"></span></b> <div class="sub-menu-container"> <ul class="sub-menu">  <li><a class="top-menu-link" href="/m/marketplace/">Company Directory</a></li> <li><a class="top-menu-link" href="/section/interviews/">Interviews with Thought Leaders</a></li> <li><a class="top-menu-link" href="/section/case-studies/">Sponsored Case Studies</a></li> <li><a class="top-menu-link" href="/m/editor-tool/">Create Company Profile</a></li> </ul> </div> </div> <div class="mobile-menu-item"> <b class="mobile-menu-item-title" onclick="this.parentElement.classList.toggle('active')">More <span class="caret"></span></b> <div class="sub-menu-container"> <ul class="sub-menu"> <li><a class="top-menu-link" href="/about/">About Us</a></li> <li><a class="top-menu-link" href="/about/team/">Our Team</a></li> <li><a class="top-menu-link" href="/about/advisory-board/">Advisory Board</a></li> <li><a class="top-menu-link" href="/about/press-citations/">Citations and Press Coverage</a></li> <li><a class="top-menu-link" href="/events/">Partner Events Calendar</a></li> <li><a class="top-menu-link" href="/advertising-media-kit/">Advertise with Us</a></li> <li><a class="top-menu-link" href="/contributor/">Write for Us</a></li> </ul> </div> </div> </nav> </div> <div id="main-user-actions">  <div class="mobile-menu-item"> <a href="/membership/" class="button-subscribe top-menu-link">Subscribe</a> </div>  <div class="mobile-menu-item last"> <a href="#" class="mobile-menu-item-title" rel="nofollow" title="Login/Join" onclick="document.getElementById('login-popup').classList.toggle('hidden')"> <span class="glyphicon glyphicon-log-in"></span> <span class="mobile-hide-m">Login/Join</span> </a> </div> </div> </div> </div> <div id="main-preheader-margin"></div> <div id="sencondary-menu-block"> <div class="container clearfix"> <nav> <ul class="text-center"> <li><a href="/topic/ai-digital/">AI & Digital</a></li> <li><a href="/topic/startups/">Startups & Deals</a></li> <li><a href="/topic/neurotech/">NeuroTech</a></li> <li><a href="/topic/clinical-trials/">Clinical Trials</a></li> <li><a href="/topic/synbio/">Biotech</a></li> <li><a href="/topic/tools-methods/">Tools & Methods</a></li> </ul> </nav> </div> </div>  <div id="main-content" class="container"> <main id="content" class="col-lg-9 col-md-8 col-sm-12 col-xs-12"> <div class="mobile-only"> </div> <article id="post-781" class="post "> <header> <h1>Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies</h1> </header> <footer class="post-meta"> <div class="tooltip"> <span class="glyphicon glyphicon-pencil"></span> by <a href="/contributor/2403/">Dimitrios Skaltsas</a> <a href="https://www.linkedin.com/in/dimitriosskaltsas/" rel="nofollow" target="_blank"> <img src="/static/img/linkedin_icon_50x50.71dcf83d1029.png" class="author-linkein-icon" /> </a> <span class="tooltip-trigger" onclick="this.parentElement.classList.toggle('tooltip-show')"> Contributor <i class="glyphicon glyphicon-info-sign"></i> </span> , <a href="/contributor/2404/">Bara Badwan</a> <a href="https://www.linkedin.com/in/bara-badwan-65598965/" rel="nofollow" target="_blank"> <img src="/static/img/linkedin_icon_50x50.71dcf83d1029.png" class="author-linkein-icon" /> </a> <span class="tooltip-trigger" onclick="this.parentElement.classList.toggle('tooltip-show')"> Contributor <i class="glyphicon glyphicon-info-sign"></i> </span> , <a href="/contributor/2405/">Panos Karelis</a> <a href="https://www.linkedin.com/in/karelis/" rel="nofollow" target="_blank"> <img src="/static/img/linkedin_icon_50x50.71dcf83d1029.png" class="author-linkein-icon" /> </a> <span class="tooltip-trigger" onclick="this.parentElement.classList.toggle('tooltip-show')"> Contributor <i class="glyphicon glyphicon-info-sign"></i> </span>    <span style="white-space: nowrap;"> <span class="glyphicon glyphicon-folder-open"></span>   </span> <span>Sponsored by <strong>Intelligencia AI</strong></span> <div class="tooltip-text"> <div class="tooltip-close" onclick="this.parentElement.parentElement.classList.toggle('tooltip-show');"></div> <p><b>Disclaimer</b>: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com. <br> Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.</p> </div> </div> <div> <span class="glyphicon glyphicon-calendar" title="Published on"></span> <time datetime="2024-04-08">April 8, 2024</time>    </em> </div> <div class="tags"> <b>Topics: </b> <a href="/topic/ai-digital/">AI & Digital</a>    </div> <div> <strong>Share: </strong>   <a target="_blank" rel="nofollow" href="https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.biopharmatrend.com/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/"> <img alt="Share in LinkedIn" src="/static/img/soc-in.7bc286fd757e.png" width="28" height="28"></a>  <a target="_blank" rel="nofollow" href="https://www.reddit.com/submit?url=https%3A%2F%2Fwww.biopharmatrend.com/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/"> <img alt="Share in Reddit" src="/static/img/soc-reddit.342e87a07115.png" width="28" height="28"></a>  <a target="_blank" rel="nofollow" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.biopharmatrend.com/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/"> <img alt="Share in X" src="/static/img/soc-x.3c80e8291cba.png" width="28" height="28"></a>  <a target="_blank" rel="nofollow" href="https://news.ycombinator.com/submitlink?u=https%3A%2F%2Fwww.biopharmatrend.com/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/"> <img alt="Share in Hacker News" src="/static/img/soc-y.587f16a5f3f3.png" width="28" height="28"></a>  <a target="_blank" rel="nofollow" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.biopharmatrend.com/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/&display=page"> <img alt="Share in Facebook" src="/static/img/soc-fb.3031a5a810f0.png" width="28" height="28" /></a>  <a target="_blank" rel="nofollow" href="mailto:?subject=Biopharmatrend.com&body=https%3A%2F%2Fwww.biopharmatrend.com/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/"> <img alt="Send by email" src="/static/img/soc-mail.41ce3608f438.png" width="28" height="28"></a>   |  <a href="/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/pdf/" target="_blank" rel="nofollow"> <span style="vertical-align: text-top; color: deepskyblue; font-size: 1.5em;" class="glyphicon glyphicon-print"></span></a> </div> </footer> <section> <p>Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike. With biotech firms often going public before generating revenue, valuations hinge on the potential for FDA approval of their assets. Herein lies the power of artificial intelligence (AI): by predicting the likelihood of success for these assets, we can uncover undervalued companies, offering a strategic edge not only to hedge funds and VCs but also to big pharma companies considering acquisitions. In this dynamic landscape, projected to see M&A activities reaching as high as $275B in 2024, the ability to discern and invest in promising biotech assets early is crucial.</p> <p>At <a href="https://www.intelligencia.ai/?utm_source=biopharmatrend&utm_medium=sponsoredarticle&utm_campaign=corporatedevelopment">Intelligencia AI</a>, our methodology offers a clear edge by delivering superior, real-time insights into the probability of success (PoS) for Phase 1 and Phase 2 assets gaining FDA approval. We used our predictions to create a virtual portfolio that generated 60% returns in one year and 3 out of the top 10 companies we highlighted were acquired.</p> <p>This advanced predictive capability is pivotal for stakeholders to identify promising acquisition and in-licensing opportunities with a higher degree of accuracy and confidence. Our methodology has proven to be highly effective as a standalone strategy and can also complement established approaches.</p> <p> </p> <h2>Achieving Results: A Glimpse Behind the Curtain</h2> <p>At Intelligencia AI, we used our <a href="https://www.intelligencia.ai/press-releases/intelligencia-ai-awarded-u-s-patent-for-its-accurate-and-transparent-probability-of-drug-success-assessments/?utm_source=biopharmatrend&utm_medium=sponsoredarticle&utm_campaign=corporatedevelopment">proprietary, patented probability of success (PoS) prediction technology</a> to create our own virtual portfolio* of publicly traded biotech companies. Our portfolio was constructed with early-stage, pre-proof-of-concept biotech companies with oncology pipelines and a market capitalization between $100M and $1B.</p> <p>Our investment strategy focused on ranking companies based on predicted overperformance against historic benchmarks and selecting the top percentile of ranked companies. The ranked list discussed here was produced algorithmically. Overall, results can be further qualified and prioritized by our team of expert analysts when further dimensions may be relevant to our partners.</p> <p style="text-align: center;"><img alt="" src="/files/uploads/2024/04/08/bpt_intelligencia_art1_img1.webp" /></p> <p style="text-align: center;"><em><small>Biotech companies ranked by their expected overperformance.</small></em></p> <p> </p> <p>Intelligencia AI’s approach has been prospectively validated with time-stamped predictions from April 21, 2023. By March 21, 2024, Intelligencia AI’s portfolio of top 40 ranked biotechs achieved a 60% return and a Sharpe Ratio of 1.83. In comparison, similar market cap companies had a 25% return, while the biotech market benchmark index (XBI-ETF) saw a 17% return, underscoring the strategy's effectiveness. This approach has also been back-tested over a 5-year period.</p> <p style="text-align: center;"><img alt="" src="/files/uploads/2024/04/08/bpt_intelligencia_art1_img2.webp" /></p> <p style="text-align: center;"><em><small>Performance of Intelligencia AI portfolio of top 40 ranked biotechs compared to the rest of the biotech market.</small></em></p> <p> </p> <p>The same methodology can be applied continuously incorporating the latest information to construct the most up-to-date portfolios. We continued to construct such time-stamped profiles. Below we highlight one constructed in late November 2023 displaying top ten picks from that portfolio. Highlights include multiple recently acquired early-stage biotechs.</p> <p style="text-align: center;"><img alt="" src="/files/uploads/2024/04/08/bpt_intelligencia_art1_img3.webp" /></p> <p style="text-align: center;"><em><small>Highlights from Intelligencia AI’s portfolio of top 10 ranked biotechs on November 28, 2023.</small></em></p> <p><br />  </p> <p><strong>Harpoon Therapeutics (HARP)</strong>, which has developed a portfolio of novel T-cell engagers, entered into a definitive agreement with Merck (MSD) on January 8, 2024.<br /> <br /> We singled out Harpoon Therapeutics’ assets in clinical development as standing out from competitive products. Both the lead candidate, HPN328 targeting T-cell engager, and HPN217 targeting B-cell maturation antigen (BCMA), were included in the acquisition.</p> <p style="text-align: center;"><img alt="" src="/files/uploads/2024/04/08/bpt_intelligencia_art1_img4.webp" /></p> <p style="text-align: center;"><em><small>PoS distribution of ongoing assets similar to Harpoon’s candidate HPN217 targets B-cell maturation antigen (BCMA). Harpoon’s candidate had been outperforming most development programs within the same indication and stage of development, belonging to the top quartile.</small></em></p> <p> </p> <p><strong>Ambrx (AMAM)</strong>, an early-stage biotech with proprietary Antibody Drug Conjugate (ADC) technology, entered into a definitive agreement with Johnson & Johnson on January 8, 2024.<br /> <br /> We singled out two of the programs currently in early-stage clinical development as highly promising. Both novel ADC candidates, ARX788 and ARX517, were part of the acquisition.<br /> <br /> <strong>Kinnate Biopharma Inc. (KNTE)</strong>, a clinical-stage precision oncology company, entered into a definitive agreement with XOMA Corporation on February 16, 2024.<br /> <br /> We highlighted two of their programs, Exarafenib and KIN-3248 treating melanoma and intrahepatic cholangiocarcinoma respectively, which had probabilities of success that far exceeded their expected historical benchmarks.</p> <p> </p> <h2>Better Predictions, Better Investment and Clinical Development Decisions With Validated PoS Assessments</h2> <p>The ability to create the above-described composite biotech scores on the basis of PoS is driven by highly accurate, prospectively validated PoS predictions for specific programs. Built on a unique, proprietary database, <a href="https://www.intelligencia.ai/solutions/saas-products/#portfolio-optimizer?utm_source=biopharmatrend&utm_medium=sponsoredarticle&utm_campaign=corporatedevelopment">Intelligencia AI’s platform</a> brings together expertly curated and harmonized clinical development, biological and regulatory data, which feeds our AI algorithms to assess drug approval and phase transition probabilities.</p> <p>Our algorithms show an 83%** accuracy in predicting FDA approvals for Phase 2 oncology programs, reaching 90% retrospectively. We achieve this performance by using standard calibration techniques and continuously validating our predictions against real FDA outcomes.</p> <p>In conducting a 4-year, ongoing prospective study, we demonstrate the high accuracy of our algorithms for early-stage development programs. In 2019, we collaborated with a leading pharmaceutical company to assess PoS for all FDA-track, industry-led, interventional Phase 1 and Phase 2 non-small cell lung cancer (NSCLC) and melanoma programs.</p> <p>We have been monitoring these programs since then, with 140 failures and 6 approvals. Our platform accurately predicted approval for four drugs, including novel ones and three receiving accelerated approvals: Amivantamab, Tepotinib, Tebentafusp, and Selpercatinib. Our PoS predictions for these programs were significantly higher than for those of similar-stage peers, even with relatively limited information at the time. Also, by time stamping the PoS assessments, we show that the accuracy of the PoS predictions has further improved in later releases of our algorithms.</p> <p style="text-align: center;"><img alt="" src="/files/uploads/2024/04/08/bpt_intelligencia_art1_img5.webp" /></p> <p style="text-align: center;"><em><small>The graphs show the distribution of approved and failed programs, based on the PoS assigned by Intelligencia AI. Our algorithms have consistently assigned a significantly higher PoS to programs that moved on to approval and lower probability to programs that eventually failed. Importantly, our accuracy has improved over time, as the comparison between 2019 (left panel) and 2022 (right panel) shows.</small></em></p> <p> </p> <h2>Conclusion and Future Outlook</h2> <p>Our AI-driven approach in assessing biotech companies based on the risk of their development portfolio constitutes an innovative approach to identify assets for acquisition and in-licensing. The returns realized with our approach highlight its accuracy and demonstrate its capability to guide timely, informed and impactful decisions. These capabilities allow us to help our partners quickly pinpoint overlooked opportunities and realize superior returns.</p> <p>As we continue optimizing the use of AI for risk assessment in drug development, we are committed to supporting life science companies in bringing groundbreaking therapies to the market and transforming patients’ lives.</p> <p><a href="https://www.intelligencia.ai/contact/?utm_source=biopharmatrend&utm_medium=sponsoredarticle&utm_campaign=corporatedevelopment">Visit intelligencia.ai to discover more and request a demo.</a></p> <p> </p> <p><em><small>* This material is provided for informational purposes only, and it is not, and may not be relied on in any manner as investment advice or as an offer to sell or a solicitation of an offer to buy an interest in any fund or investment vehicle managed by Intelligencia AI or any other Intelligencia entity. The information and data are as of the publication date unless otherwise noted, and Intelligencia has no obligation to update such information or data. Certain information contained herein has been obtained from third-party sources. Although such content is believed to be reliable, it has not been independently verified as to its accuracy or completeness and cannot be guaranteed.</small></em></p> <p><em><small>** Based on Intelligencia AI predictions as of May 2022 for oncology programs with definite announcements in 2023.</small></em></p> <p> </p> <div class="product-list"> <a href="/m/company/intelligencia-ai/" class="btn btn-bpt-white">Intelligencia AI</a> </div> <p> <b>Topics: </b> <a href="/topic/ai-digital/">AI & Digital</a>    </p> </section> </article> <div style="margin: 1em 0 2em; padding: 0.5em 0;"> <strong>Share: </strong>   <a target="_blank" rel="nofollow" href="https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.biopharmatrend.com/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/"> <img alt="Share in LinkedIn" src="/static/img/soc-in.7bc286fd757e.png" width="28" height="28"></a>  <a target="_blank" rel="nofollow" href="https://www.reddit.com/submit?url=https%3A%2F%2Fwww.biopharmatrend.com/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/"> <img alt="Share in Reddit" src="/static/img/soc-reddit.342e87a07115.png" width="28" height="28"></a>  <a target="_blank" rel="nofollow" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.biopharmatrend.com/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/"> <img alt="Share in X" src="/static/img/soc-x.3c80e8291cba.png" width="28" height="28"></a>  <a target="_blank" rel="nofollow" href="https://news.ycombinator.com/submitlink?u=https%3A%2F%2Fwww.biopharmatrend.com/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/"> <img alt="Share in Hacker News" src="/static/img/soc-y.587f16a5f3f3.png" width="28" height="28"></a>  <a target="_blank" rel="nofollow" href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.biopharmatrend.com/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/&display=page"> <img alt="Share in Facebook" src="/static/img/soc-fb.3031a5a810f0.png" width="28" height="28" /></a>  <a target="_blank" rel="nofollow" href="mailto:?subject=Biopharmatrend.com&body=https%3A%2F%2Fwww.biopharmatrend.com/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/"> <img alt="Send by email" src="/static/img/soc-mail.41ce3608f438.png" width="28" height="28"></a> </div> <div class="subscribe-block"> <div class="subscribe-inner"> <h3 style="line-height:1.5; font-weight: 900;"> <span style="font-weight: 900">Get Exclusive Insights Into Your Inbox</span> <br> <span style="font-weight: normal;">join 7000+ BPT insiders</span> </h3> <br> <div> <a style="font-size: 1.25em;width:17em; text-align: center; border-color: white; color: white; font-weight: 900" href="#" onclick="toggleMailingPopup(true)" class="btn">Subscribe</a> </div> </div> </div> <section id="comments"> </section> </main> <aside id="main-sidebar" class="col-lg-3 col-md-4 col-sm-12 col-xs-12"> <section class="well"> <h4>Latest Articles</h4> <ul> <li><a href="/post/1025-what-will-be-the-key-trends-in-ai-innovation-in-the-pharmaceutical-industry-in-2025/">What will be the key trends in AI innovation in the Pharmaceutical Industry in 2025?</a></li> <li><a href="/post/1007-ai-is-key-to-democratizing-drug-discovery/">AI Is Key to Democratizing Drug Discovery</a></li> <li><a href="/post/1006-elsevier-partners-with-pistoia-alliance-to-tackle-ai-challenges-in-drug-discovery/">Elsevier Supports Pistoia Alliance to Tackle AI Challenges in Drug Discovery</a></li> <li><a href="/post/1004-evogene-partners-with-google-cloud-to-build-ai-model-for-small-molecule-discovery/">Evogene Partners with Google Cloud to Build AI Model for Small Molecule Discovery</a></li> <li><a href="/post/1003-absci-and-twist-bioscience-collaborate-to-design-a-novel-antibody-with-generative-ai/">Absci and Twist Bioscience Collaborate to Design a Novel Antibody with Generative AI</a></li> <li><a href="/post/1002-novo-nordisk-foundation-launches-denmarks-first-ai-supercomputer-to-accelerate-drug-discovery-and-innovation/">Novo Nordisk Foundation Launches Denmark鈥檚 First AI Supercomputer to Accelerate Drug Discovery and Innovation</a></li> </ul> </section> </aside> </div> <footer id="main-footer"><div class="container"> <div class="row"> <div class="col-12 col-sm-6 col-lg-3"> <h4 class="footer-logo"><span style="font-weight: 900">BiopharmaTrend</span>.com</h4> <div style="margin-bottom: 1.25em" class="footer-logo-slogan">Where Tech Meets Bio</div>  <div style="margin-bottom: 0.5em;"><a href="#main-footer" onclick="toggleMailingPopup(true)" style="color: lemonchiffon"> <img src="/static/img/sm-mail.a3210e82fe37.png" alt="mail" width="32" height="32" />  <b>Newsletter</b> </a></div> <div style="margin-bottom: 0.5em"><a href="https://www.linkedin.com/company/biopharmatrend-com/" rel="nofollow" target="_blank"> <img src="/static/img/sm-in.fb9ea368635d.png" alt="in" width="32" height="32" />  LinkedIn </a></div> <div style="margin-bottom: 0.5em"><a href="https://twitter.com/BiopharmaTrend" rel="nofollow" target="_blank"> <img src="/static/img/sm-x.9f3327271e1a.png" alt="x" width="32" height="32" />  X </a></div> <div style="margin-bottom: 0.5em"><a href="https://news.google.com/publications/CAAqBwgKMOaRugsw86zRAw?hl=en-US&gl=US&ceid=US:en" rel="nofollow" target="_blank"> <img src="/static/img/sm-gnews.ac9eb4674c84.png" alt="gnews" width="32" height="32" />  Google News </a></div> <div><a href="/rss/" rel="nofollow" target="_blank"> <img src="/static/img/sm-rss.bcd2cefd2eba.png" alt="rss" width="32" height="32" />  RSS Feed </a></div> </div> <div class="col-12 col-sm-6 col-lg-3"> <h4>About</h4> <hr> <nav> <ul class="list-unstyled"> <li><a href="/about/">What we do</a></li> <li><a href="/editorial-calendar/">Editorial Calendar</a></li> <li><a href="/about/press-citations/">Citations and Press Coverage</a></li> <li><a href="/terms-of-use/">Terms of Use</a></li> <li><a href="/privacy-policy/">Privacy Policy</a></li>  <li><a href="/about/disclaimer/">Disclaimer</a></li> </ul> </nav> </div> <div class="col-12 col-sm-6 col-lg-3"> <h4>We Offer</h4> <hr> <nav> <ul class="list-unstyled"> <li><a href="/premium-content/"><b style="color: lemonchiffon">Premium Content</b></a></li> <li><a href="/m/marketplace/">BioTech Scout</a></li> <li><a href="/our-products/">Reports</a></li> <li><a href="/section/interviews/">Interviews</a></li> <li><a href="/events/">Partner Events</a></li> <li><a href="/section/case-studies/">Case Studies</a></li> </ul> </nav> </div> <div class="col-12 col-sm-6 col-lg-3"> <h4>Opportunities</h4> <hr> <nav> <ul class="list-unstyled"> <li><a href="/membership/">Membership</a></li> <li><a href="/advertising-media-kit/">Advertise</a></li> <li><a href="/m/editor-tool/">Submit Company</a></li> <li><a href="/contributor/">Write for Us</a></li> <li><a href="/guest-blog/guidelines/">Author Guidelines</a></li> <li><a href="/a/contact/">Contact Us</a></li> </ul> </nav> </div> </div> <hr> <div class="text-right">© BPT Analytics LTD 2024</div> </div></footer> <div id="bpt-consent"><div class="container"> <div class="row"> <div class="col-12 col-md-6 col-lg-8"> We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our <a href="/cookies-policy/">cookies policy</a>. </div> <div class="col-12 col-md-6 col-lg-4 text-right"> <button class="btn btn-primary btn-sm" type="button" onclick="changeConsent('analytics')" style="white-space:unset">Agree</button> </div> </div> </div></div> <div id="login-popup" class="hidden popup"> <div class="close" onclick="this.parentElement.classList.add('hidden')"><i class="glyphicon glyphicon-remove"></i></div> <div class="popup-content" style="width: 25em;"> <form method="post" class="api-form" action="/a/login/?next=/post/781-patented-ai-platform-identifies-promising-early-stage-biopharma-assets-and-companies/"></form> </div> </div> <div id="subscription-popup" class="hidden popup"> <div class="close" onclick="this.parentElement.classList.add('hidden')"><i class="glyphicon glyphicon-remove"></i></div> <div id="subscription-popup-iframe" class="popup-content" style="width: 25em;"> </div> </div> <div id="scroll-top-pixel-anchor"></div> <button id="go-top" onclick="window.scrollTo({top: 20, left: 0, behavior: 'smooth'})">^</button> <script src="https://ajax.googleapis.com/ajax/libs/jquery/3.3.1/jquery.min.js"></script> <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.4.1/js/bootstrap.min.js"></script> <script src="/static/js/main.df923d2272d3.js"></script> <script type="text/javascript"> if ( "IntersectionObserver" in window && "IntersectionObserverEntry" in window && "intersectionRatio" in window.IntersectionObserverEntry.prototype ) { let observer = new IntersectionObserver(entries => { if (entries[0].boundingClientRect.y < 0) { document.body.classList.add("scroll-top"); } else { document.body.classList.remove("scroll-top"); } }); observer.observe(document.getElementById("scroll-top-pixel-anchor")); } </script> <script src="/static/js/blog-ajax.eb8cbd906073.js"></script> <script> const comments_url = "/blog-api/comments/post-781"; post_comments_load(); </script> </body> </html>

CINXE.COM

Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies